Acceptance of weight loss medication in patients with atypical hyperplasia or carcinoma of the endometrium as part of the fertility preservation treatment: A qualitative study
Weight-loss medication may be an acceptable adjunct to progestin treatment in this population, if preceded by a thorough risk-benefit discussion and early counselling on the role and management of obesity in EC/AH.
Authors
- Oleksandra Dzyubak
- Soyoun Rachel Kim (ORCID: https://orcid.org/0000-0002-5694-5439)
- Dionne Gesink (ORCID: https://orcid.org/0000-0002-8874-0470)
- Oluwanifemi O. Adeoye
- Sarah E. Ferguson
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Public Health Ontario (CA)
- Sinai Health System (CA)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1016/j.gore.2026.102058
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00